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Background: The Y-box protein MSY3/Csda represses myogenin transcription in skeletal muscle by binding a highly
conserved cis-acting DNA element located just upstream of the myogenin minimal promoter (myogHCE). It is not known
how this MSY3 activity is controlled in skeletal muscle. In this study, we provide multiple lines of evidence showing that
the post-translational phosphorylation of MSY3 by Akt kinase modulates the MSY3 repression of myogenin.
Methods: Skeletal muscle and myogenic C2C12 cells were used to study the effects of MSY3 phosphorylation in vivo
and in vitro on its sub-cellular localization and activity, by blocking the IGF1/PI3K/Akt pathway, by Akt depletion and
over-expression, and by mutating potential MSY3 phosphorylation sites.
Results: We observed that, as skeletal muscle progressed from perinatal to postnatal and adult developmental
stages, MSY3 protein became gradually dephosphorylated and accumulated in the nucleus. This correlated well
with the reduction of phosphorylated active Akt. In C2C12 myogenic cells, blocking the IGF1/PI3K/Akt pathway
using LY294002 inhibitor reduced MSY3 phosphorylation levels resulting in its accumulation in the nuclei.
Knocking down Akt expression increased the amount of dephosphorylated MSY3 and reduced myogenin
expression and muscle differentiation. MSY3 phosphorylation by Akt in vitro impaired its binding at the MyogHCE
element, while blocking Akt increased MSY3 binding activity. While Akt over-expression rescued myogenin
expression in MSY3 overexpressing myogenic cells, ablation of the Akt substrate, (Ser126 located in the MSY3 cold
shock domain) promoted MSY3 accumulation in the nucleus and abolished this rescue. Furthermore, forced
expression of Akt in adult skeletal muscle induced MSY3 phosphorylation and myogenin derepression.
Conclusions: These results support the hypothesis that MSY3 phosphorylation by Akt interferes with MSY3 repression
of myogenin circuit activity during muscle development. This study highlights a previously undescribed Akt-mediated
signaling pathway involved in the repression of myogenin expression in myogenic cells and in mature muscle. Given
the significance of myogenin regulation in adult muscle, the Akt/MSY3/myogenin regulatory circuit is a potential
therapeutic target to counteract muscle degenerative disease.
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Basic helix-loop-helix (bHLH) myogenic regulatory factors
coordinate the correct function and organization of many
skeletal muscle functions. These require precise control
both at the transcriptional and post-transcriptional level.
Among the myogenic bHLH factors, myogenin is crucial
in the embryo, in fetal and in adult life, due to its many
functions in regulating skeletal muscle growth, maturation
and metabolism [1–10]. Although it has been reported
that multiple mechanisms control myogenin in postnatal
muscle [11–15], the signaling that specifically controls
myogenin expression levels in adult skeletal muscle is not
yet fully known. We have previously shown that MSY3/
Csda binds a highly conserved cis-acting element located
upstream of the myogenin promoter (myogHCE) and
regulates the postnatal down-regulation of myogenin [16].
MSY3 (MSY4, YB-2, CSDA, dbpA, ZONAB) is a
member of the cold shock domain (CSD) family of pro-
teins also known as Y-box proteins, which are evolution-
arily conserved proteins that function as transcription
factors and regulators of RNA metabolism and protein
synthesis. Y-box proteins act via diverse mechanisms, as
they work by DNA binding and non-DNA binding
mechanisms. Moreover, they bind single-stranded DNA
and RNA and are involved in both gene repression and
activation [17–20]. MSY3 is a DNA binding protein, which
acts as a transcriptional repressor. It has been extensively
studied in tissues where it is highly expressed, including
skeletal muscle where two isoforms of MSY3 (long and
short), which differ by a single exon, are present [16, 21–23].
Possible MSY3 mechanisms of action have been studied in
cell culture studies. In particular, in fibroblasts MSY3
represses VEGF expression by preferentially binding
single-stranded sense DNA of the hypoxia responsive re-
gion (HRR) of the VEGF promoter [24]; it regulates prolif-
eration and density in epithelial cells, by shuttling between
the tight junction and the nucleus, where it regulates the
expression of cell cycle progression genes [25–27]. It is
also upregulated in epithelial cancers and promotes prolif-
eration in neoplastic cells [28, 29]. Although it is highly
expressed in skeletal muscle and heart, very little is known
about the role of MSY3 in the muscle gene regulatory net-
work. In skeletal muscle we showed that MSY3 binds,
in vitro and in vivo, the myogHCE sequence, a conserved
regulatory module located upstream of the myogenin
promoter and specifically regulates myogenin expression
[16]. Additionally, myogHCE deletion analyzed using
reporter transgenic mice, led to a persistence of myogenin
expression along the muscle fiber during the period of
muscle maturation [16]. These results show that both
MSY3 and the myogHCE play a crucial role in myogenin
down-regulation that occurs during the refinement of
synaptogenesis, when AChR expression becomes re-
stricted at synaptical sites in the muscle fiber [30, 31].Akt (or protein kinase B (PKB)) is a family of versatile
serine/threonine kinases (Akt1, Akt2, and Akt3). They
play a pivotal role in numerous biological processes,
such as cell growth, proliferation and survival, and hu-
man diseases such as cancer and type 2 diabetes. Upon
its activation, which involves tyrosine kinase receptors
and signaling events, Akt binds and phosphorylates a
wide range of transcription factors altering their sub-
cellular localization and thus leading to their activation
or inhibition [32–34]. Multiple findings indicate that Y-
box protein signaling involves the phosphatidylinositol
3-kinase (PI3K)/Akt pathway, which modulates their ac-
tivity mainly by regulating their translocation between
nucleus and cytoplasm [24, 29, 35–38]. PI3K signaling
pathway is essential for skeletal muscle growth during
development and regeneration after injury regulating
myoblast proliferation and fusion, muscle gene expres-
sion, and post-mitotic growth of myotubes [39, 40]. In
adult muscle, the Akt signaling cascade controls loss of
muscle mass by inhibiting protein degradation through
phosphorylation and inactivation of the FoxO family of
transcription factors [41, 42]. Akt is also activated during
adaptive and IGF-induced myotube hypertrophy and can
prevent loss of muscle mass by promoting protein synthe-
sis through the activation of the mTOR pathway [43–45].
Numerous direct and indirect substrates of the PI3K path-
way have been characterized in skeletal muscle: key
regulatory proteins involved in translation and protein
synthesis, effectors of protein degradation such as ubiqui-
tin ligases and also transcription factors and chromatin
remodeling complexes involved in skeletal muscle differ-
entiation and growth [39, 40, 46–55].
During muscle maturation, MSY3 becomes dephos-
phorylated and accumulates in the nuclei of muscle fi-
bers and represses myogenin [16]. This correlates with
myogenin down-regulation observed as muscle proceeds
through advanced stages of postnatal life. Given the role
of MSY3 in skeletal muscle differentiation and Akt’s cap-
acity to regulate Y-box protein activity, we asked if the
PI3K pathway controls MSY3 activity to repress myo-
genin during muscle differentiation and in adult life. In
this study, by using specific inhibitors of the PI3K path-
way, we showed that Akt phosphorylates the MSY3
CSD in myogenic cells and subsequently MSY3 is se-
questered in the cytoplasm. Phosphorylation by Akt
and subsequent cytoplasmic translocation of MSY3 re-
sults in derepression of myogenin, which is required for
progression of differentiation. Akt over-expression in
adult muscle induces MSY3 phosphorylation and upre-
gulates myogenin expression. These findings in the
C2C12 cell culture system and postnatal and mature
muscle correlate with myogenin down-regulation ob-
served as muscle proceeds throughout advanced stages
of postnatal life. Furthermore, they suggest a role for
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myogenin activity in adult skeletal muscle function.Methods
Cell, treatments, transfections, and RNA interference
C2C12 cells (ATCC) were cultured in DMEM supple-
mented with 20 % FBS (growth medium (GM)) and induced
to differentiate with DMEM supplemented with 2 % HS
(differentiation medium (DM)). SB203580, LY294002 and
Rapamycin were purchased from Calbiochem. Wortmannin,
PD98059, KN-62 and KN-93 were purchased from Sigma.
Transfections of C2C12 cells were performed with FuGene
reagent (Roche). To generate and maintain stable clones,
selection of C2C12 cells was performed with G418 at a
concentration of 400 μg/ml and puromycin at 2 μg/ml.
Gene expression was determined by qRT-PCR as described
previously [16]. Down-regulation of Akt1 and Akt2 by RNA
interference was achieved as previously described [55].Immunofluorescence
C2C12 cells were fixed in 4 % paraformaldehyde (10
min at 4 °C) and then treated with 0.15 % Triton X-100
in PBS for 5′ at RT. After re-hydration with PBS, they
were blocked with 10 % NGS for 1 h at RT and then
processed for immunofluorescence (IF) with an MSY3
rabbit antiserum ZONAB (Zymed) [56], diluted 1:100
in 1.5 % normal goat serum in PBS followed by Alexa
Fluor 594 goat anti-rabbit (Invitrogen). For FLAG IF, a
mouse anti-FLAG M2 (Sigma) was used at the dilution
of 1:400, followed by Alexa Fluor 488 goat anti-mouse
(Invitrogen) incubation. Also mouse anti-MHC (MF20)
(Developmental Studies Hybridoma Bank) and rabbit
anti-histoneH3 (Sigma) were used. IF images were
exported in Tiff format, and fluorescence intensities in
the nuclear and cytoplasmic regions were quantified
using ImageJ. Background-corrected N/C ratios were
calculated from mean fluorescence intensities measured
within a small square or circular region of interest
placed within the nucleus, cytoplasm, and outside of
each cell. Due to LY294002 effects on proliferation,
measurements on LY 80 % (Fig 3) were performed only
in those areas where the cells reached confluence.
Cross sections of limbs of 2-day-aged pups (2 pn) and
TA of 1-month-aged mice (1 M) were fixed in metha-
nol for 10 min at −20 °C and then treated with 0.2 %
Triton X-100 in PBS for 5′ at RT. After re-hydration
with PBS, they were blocked with 4 % BSA for 1 h at
RT and then processed for immunofluorescence (IF)
with ZONAB, diluted 1:100, and mouse anti-caveolin 3
(BD), diluted 1:500, in 4 % BSA-PBS followed by Alexa
Fluor 594 goat anti-rabbit and Alexa Fluor 488
(Invitrogen).Immunoblot analysis and immunoprecipitation
Nuclear and cytosolic protein extracts from C2C12 cells
and from skeletal muscle were isolated with the Nuclear
Extract Kit (Active Motif). Proteins were fractionated by
electrophoresis on 10 % Novex Tris-glycine polyacrylamide
gel (Life Technologies). For MSY3 phosphorylation analysis,
8 % Novex Tris-glycine polyacrylamide gels were used (Life
Technologies). They were electroblotted to nitrocellulose
membrane and reacted with rabbit anti-MSY3 (ZONAB)
(Life Technologies), mouse anti-FLAG M2 (Sigma), mouse
anti-α − tubulin and mouse anti-GAPDH (Sigma-Aldrich),
mouse anti-myogenin (FD5, IOWA Hybridoma bank),
anti-phospho-Akt (Ser473), and anti-Akt (Cell Signaling).
Immunoreactivity was determined using the ECL method
(Life Technologies) with the reagents provided according to
the manufacturer’s instructions. Densitometry calculations
were done by measurements of band intensities using Ima-
geJ, verifying for background and non-saturation. Values
are expressed as the integrals (area*means density) of each
band (normalized to weakest band).
For immunoprecipitation (IP), protein extracts (50 μg)
from skeletal muscle (8 and 15 pn) isolated as described
above, were incubated for 2 h at 4 °C with 2.5 μg of
anti-MSY3 Ab, ZONAB, previously coated to Dyna-
beads® M-280 Sheep anti-Rabbit IgG (Life Technologies).
The immunocomplexes were analyzed by Western blot
as described above, together with not immunoprecipi-
tated extract (Input) and unconjugated IgG.Protein dephosphorylation assay
Forty micrograms of extracts were incubated with differ-
ent amounts of Antarctic Phosphatase (Roche), in the
presence of its reaction buffer 10× for 30 min at 37 °C
and directly analyzed or immunoprecipitated and ana-
lyzed by Western blot as described above.Plasmids
The MSY3FLAG and mutated forms were generated by
PCR amplification from the parental pcDNA3-MSY3 HA
plasmid (16) and then cloned in frame in the N-p3XFLAG-
CMV vector using the following oligos: FLAGFOR 5′
GAATTCGAGCGAGGCGGGCGAGGCCACC 3′; FLAG
REV 5′TCTAGACGGTGCCTGGGAGCCAGGGTC 3′. G
ST-MSY3 fusion proteins were generated as previously de-
scribed [16].Preparation of recombinant and nuclear protein and gel
shift analysis
EMSA experiments were performed according to proto-
cols previously described [16]. Reactions were analyzed
on 8 % non-denaturing polyacrylamide gel.
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The Escherichia coli strain BL21 transformed with pGST-
MSY3 was induced with isopropyl-thio-β-D-galactopyra-
noside to produce recombinant GSTMSY3 protein. The
fusion proteins were purified on glutathione-sepharose
beads as described by the manufacturer (Promega). Phos-
phorylation of MSY3 was determined by incubating 50 ng
of recombinant GSTMSY3 protein with Akt and GSK3β
active proteins (Upstate), in a mixture containing 10 mM
MgCl2, 2 mM DTT, 5 mM β-glycerolphosphate, 0.1 mM
Na3VO4, 25 mM Tris–HCl, pH 7.5 and 50 μCi [γ 32P]
ATP in an in vitro phosphorylation assay. Kinase reactions
were incubated at 30 °C for 30 min, and 32P labeled pro-
teins were examined by 12 % SDS/PAGE and detected
after exposure of gels to X-ray films. For preparation of
cold kinase proteins, kinase reactions were performed by
incubation with or without active Akt and GSK3β, in pres-
ence of 0.5 mM ATP.
Site-directed mutagenesis
The FLAGMSY3 mutant constructs Ser126Ala and
Ser328Ala were synthesized and sequenced by GenScript
Corporation (Piscataway, NJ, USA; www.genscript.com).
Chromatin immunoprecipitation assay
ChIP in C2C12 cells was performed as previously de-
scribed [16], and in adult muscle, the following modifi-
cations were introduced: 100 mg of TA from an adult
mouse (3-month-aged 3MM) was dissected 7 days post-
electroporation, minced, and then fixed with 1 % formal-
dehyde for 15 min. After fixation, glycine was added to a
final concentration of 0.125 M. The tissue was then
homogenized in PBS using the Micro-Dismembrator U
(Sartorius). Nuclei were collected in lysis buffer and son-
icated. The average size of the fragments was approxi-
mately 400 bp. We used 2 μg of anti-ZONAB/MSY3
(Life Technologies) and qRT-PCR was performed as de-
scribed above. Primers used for amplification were as fol-
lows: myogenin promoter Forward 5′-CCCTGCCCCACA
GGGGCTGTG-3′ Reverse 5′-ACGCCACAGAAACCTG
AGCCC-3′; IGH enhancer Forward 5’-GCCGATCAGA
ACCAGAACACCTGC-3′Reverse 5′-TGGTGGGGCTGG
ACAGAGTGTTTC-3′.
In vivo electroporation
Animal experiments were conducted after approval from
the Institutional Animal Use and Care Committee
(IACUC) at California Institute of Technology, (protocol
n.1565). TA muscle was electroporated as previously de-
scribed [16]. Expression vectors were injected with a 0.5-
m insulin syringe through a 27-gauge needle into the TA
muscles of 3MM C57BL6 mice (20 μg of myristoylated
Akt expressing vector or pcDNA3 in a constant volume
of 20 μl of PBS).Results
MSY3 is progressively dephosphorylated as skeletal
muscle matures
We previously demonstrated that MSY3 protein expres-
sion progressively increased as muscle matures, from late
stages of fetal development (15 dpc) to the mature stages
of muscle growth in postnatal life (2 months old, 2MM).
A Western blot analysis showed that the migration pattern
of MSY3 protein (long isoform) shifts from a multi-band
to a single lower molecular weight band in the nuclear
extract of leg muscle, between very early stages of postna-
tal development (8 pn) and later stages (15 pn) [16]. We
interpreted this modification as a result of the protein
phosphorylation state change. We analyzed the MSY3
protein-banding pattern from 6–15 days postnatal extracts
and inferred the time of shift from a multi-band to a single
band migration pattern around the ninth day of postnatal
life (Fig. 1a). During progression from fetal to adult stages,
myogenin expression is severely reduced along the muscle
fiber, as described previously [30, 57], and shown in
Additional file 1: Figure S1. To investigate whether this
change in MSY3 migration pattern is caused by the loss of
a phosphate group, we incubated protein extracts from
limbs of 16 dpc embryos with Antarctic Phosphatase
(AP). Upon treatment with AP, MSY3 protein migrated as
a single band compared to the multiple bands observed in
the untreated sample (Fig. 1b), suggesting that MSY3 is
phosphorylated during muscle development. Analysis of
MSY3 immunoprecipitated protein from skeletal muscle
extracts of 8 pn and 15 pn mice showed the same migration
observed in skeletal muscle (Additional file 1: Figure S2A).
Treatment of the immunoprecipitated MSY3 protein with
AP affected its migration pattern similar to the input control
(non-immunoprecipitated) MSY3 protein (Additional file 1:
Figure S2B).
We then asked if the phosphorylated and dephosphory-
lated forms of MSY3 protein segregated in different com-
partments of muscle fibers throughout perinatal and
mature developmental stages. Translocation from nucleus
to the cytoplasm and consequent activation is indeed the
main effect of phosphorylation on many transcription fac-
tors including Y-box proteins [29, 36, 58]. By nuclei-
cytosol fractionation, we observed that the dephosphory-
lated MSY3 protein progressively accumulates in the
nuclei of muscle fibers from fetal and perinatal stages to
mature developmental stages (1 month old, 1 M). During
the same time, we observed a corresponding reduction in
the phosphorylated form of MSY3 in the cytosol (Fig. 1c).
Using IF, we observed nuclear MSY3 protein accumulation
in TA cross sections of younger (2 pn) and adult mice (1
month old, 1 M). The images show much more MSY3
localization in the adult muscle fibers as compared to the
nuclei of muscle fibers of younger mice (Fig. 1d; Additional
file 1: Figure S3). An estimation of the MSY3 positive-
Fig. 1 MSY3 is progressively dephosphorylated and accumulates in the nuclei in skeletal muscle after birth. a Left: Western blot with anti-MSY3 (ZONAB)
protein extracts of limb and TA muscle at different postnatal days (pn). α-tubulin was used as normalizer. Right: densitometry calculations for MSY3 faster
(dephosph) and slower (phosph) migration bands of the Western blot on the left, normalized by α-tubulin. Figure displays results representative from three
independent experiments. *P<0.01 by Student’s t test. bWestern blot with extracts from 15 dpc embryo limbs treated with Antarctic Phosphatase (AP), 1
unit and 5 units, and probed with anti-MSY3 Ab (ZONAB). c Western blots of nuclear and cytosolic fractions of protein extracts of limb muscle at fetal (15
dpc), postnatal (pn), and mature, 1 month (1 M), stages. Histone H3 was used as normalizer of the nucleic fraction and GAPDH as normalizer of the
cytosolic fraction. d Left: expression of MSY3 evaluated by IF with anti-MSY3 Ab, ZONAB, in cross sections of limbs of 2-day-aged pups (2 pn) and TA of 1-
month-aged mice (1 M). The images merge MSY3 expression (red), caveolin 3 expression (green), and Hoechst nuclei staining (blue). MSY3 localization in
nuclei is labeled in purple. Scale bars = 100 μm. On the right, high magnification images (corresponding to dotted white squares) show staining of few
muscle fibers. Scale bar = 40 μm. White arrows indicate sporadic MSY3 nuclear accumulation in 2 pn limb cross sections. Right Graph quantifies MSY3
positive nuclei over the total nuclei in cross sections of limbs of 2-day-aged pups (2 pn) and TA of 1-month-aged mice (1 M)
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adult fibers as MSY3 positive while only a few interstitial
nuclei (10 % of total) in the younger fibers were positive for
MSY3 (Fig. 1d; Additional file 1: Figure S3). However, dueto technical difficulties, we could not substantiate expres-
sion in the cytosolic fraction of the fibers as shown by the
nuclei-cytosol fractionation shown in Fig. 1c. In adult
muscle fiber, MSY3 expression is detectable in almost all
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(Fig. 1d). Our results indicate that dephosphorylated MSY3
migrates progressively in the nucleus as the muscle grows
and matures. MSY3 dephosphorylation and segregation in
the nuclei occurs concomitantly with myogenin down-
regulation. In retrospect, these data support the hypothesis
that phosphorylation and subsequent localization of MSY3
in the cytoplasm is responsible for modulating MSY3 activ-
ity as a repressor of myogenin expression.
MSY3 is phosphorylated by Akt in C2C12 cells
In order to determine the mechanism responsible for
MSY3 phosphorylation in skeletal muscle, we analyzed
MSY3 protein expression and migration patterns in
C2C12 myogenic cells by Western blot analysis. MSY3
protein (long isoform), detected with the polyclonal anti-
body ZONAB, is expressed at the same levels in prolifer-
ating (GM) and differentiated for 48 h (DM) C2C12 cellsFig. 2 MSY3 is phosphorylated by Akt in C2C12. a Left: multi-band migration
myoblasts (GM) and myotubes (DM) treated with 1 unit of Antarctic Phospha
normalizer. Right: densitometry calculations for faster (dephosph) and slower
α-tubulin. b Left: Western blot probed with anti-MSY3 Ab (ZONAB) and anti-m
two different (20 μM and 30 μM) concentrations of LY294002 (LY). α-tubulin w
(dephosph) and slower (phosph) migration bands of the Western blot on the le
anti-MSY3 and anti-myogenin Abs in protein extracts of C2C12 grown in DM fo
oligos against of Akt 1 and Akt 2 (Akti), demonstrates that Akt activity is respons
myogenin, and MSY3 faster (dephosph) and slower (phosph) migration bands o
reduction of Akt of 75 %. Figure displays results representative from three indep
phosph P<0.01; myogenin P<0.05 by Student’s t test(Fig. 2a). We observed that MSY3 migrates as multiple
forms in both conditions, GM and DM. Also, densitom-
etry measurements of untreated extracts show that the
dephosphorylated form of MSY3 is more prominent in
myoblasts (GM) than in myotubes (DM) (Fig. 2a). After
in vitro treatment of C2C12 extracts with AP, MSY3
protein shifted to a single faster migrating form. This in-
dicates that both phosphorylated and the dephosphory-
lated forms of MSY3 are present in C2C12 myogenic
cells (Fig. 2a). We then tested the effects of LY294002
(LY), an inhibitor of the PI3K/Akt pathway that also in-
hibits myogenin expression and myogenic differentiation
[52, 55], on MSY3 phosphorylation in vivo (Additional
file 1: Figure S4A, B). Treatment with LY reduced MSY3
basal phosphorylation in C2C12 myoblasts (Fig. 2b).
However, we observed that the highest concentration of
LY tested (30 μM) resulted in a pronounced reduction of
MSY3 expression. We observed no changes in the MSY3pattern is shown in the Western blot with protein extracts of C2C12
tase (AP), probed with anti-MSY3 Ab (ZONAB). α-tubulin was used as
(phosph) migration bands of the Western blot on the left, normalized by
yogenin Ab with protein extracts of C2C12 myoblasts (GM) treated with
as used as normalizer. Right: densitometry calculations for faster
ft, normalized by α-tubulin. c Left: immunoblot with an anti-Akt total, an
r 36 h, transfected with scrambled RNAi oligos (Ki) and RNA interfering
ible for MSY3 phosphorylation. Right: densitometry calculations for Akt,
f the Western blot on the left, normalized by α-tubulin. We estimated a
endent RNAi experiments. Akt P<0.01; MSY3 dephosph P<0.05; MSY3
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C2C12 cells were treated with other kinase inhibitors, in-
volved in muscle differentiation or hypertrophy such as
p38 mitogen-activated protein kinase (p38MAPK) inhibi-
tor (SB203580), mitogen-activated protein kinase kinase
(MEK) inhibitor (PD98059), or calcium/calmodulin-
dependent protein kinase (CAMKII) inhibitors (KN-62;
KN-93) (Additional file 1: Figure S4A, B, D, E). Inhibition
of the IGF1/PI3K/Akt pathway upstream of Akt by treat-
ment with the PI3K pathway inhibitor, wortmannin,
showed a reduction in MSY3 phosphorylation (Additional
file 1: Figure S4C). In addition, treatment with rapamycin,
the mTOR inhibitor that blocks the PI3K pathways down-
stream of Akt, did not alter the ratio of phosphorylated/
dephosphorylated MSY3 protein (Additional file 1: Figure
S4C), although both wortmannin and rapamycin inhibit
myogenic differentiation (Additional file 1: Figure S4A).
The observation that only the PI3K inhibitor altered the
phosphorylated/dephosphorylated MSY3 levels argues for
a role for Akt in phosphorylating the Y-box protein MSY3
in myogenic cells. This conclusion is in agreement with
the previously documented role of Akt in phosphorylating
and regulating functions of Y-box proteins in other cell
types [29, 35, 38].
To demonstrate that Akt is responsible for MSY3
phosphorylation, we knocked down Akt1 and Akt2 ex-
pression by RNA interference in C2C12 cells, since both
kinases are involved in regulating the myogenic program
[54, 59, 60]. Upon reduction of Akt expression, esti-
mated at 75 %, we observed a strong decrease in the
amount of the phosphorylated MSY3 protein (Fig. 2c).
We also observed a concomitant reduction of myogenin
protein expression (Fig. 2c) and an impairment of myo-
genic differentiation (Additional file 1: Figure S4F).
Based on these data, we hypothesize that Akt is respon-
sible for MSY3 phosphorylation in myogenic cells and
through MSY3 plays an indirect role in regulating myo-
genin activity.
Dephosphorylated MSY3 accumulates in C2C12 nuclei
Although MSY3 is a nucleic acid binding protein, in epi-
thelial cells, it is sequestered in the cytosol by a tight
junction-associated protein, ZO-1, which controls its ac-
cumulation and activity as a transcription factor in the
nuclei [25]. This suggests that sub-cellular localization of
MSY3 is a possible mechanism for regulating MSY3
functions. Phosphorylation by Akt is a requirement for
initiating sub-cellular trafficking of many Akt targets, in-
cluding the Y-box proteins [29, 36]. To investigate the
role of Akt in MSY3 intracellular distribution in myo-
genic cells, we treated proliferating (GM) and differenti-
ated C2C12 cells (DM) with the Akt inhibitor LY and
detected MSY3 protein localization by IF with ZONAB.
Fluorescence images of untreated C2C12 cells showedthat MSY3 is not localized in the nuclei and is dis-
persed in the cytoplasm, both in myoblasts and myo-
tubes, with some exceptions of selective nuclear
localization (0.1 %, white arrow in Additional file 1:
Figure S5A). To examine MSY3 localization in more
detail, we quantified the extent of fluorescence ob-
served in the cytoplasm and nucleus from confocal sec-
tions and calculated the nuclear/cytoplasmic (N/C)
ratio for 60–80 cells across five independent experi-
ments (Fig. 3c). This analysis showed that, although a
high variability exists in the N/C ratio across different
experiments in untreated cells, MSY3 preferentially lo-
calized in the cytosol or was equivalently distributed
between nucleus and cytosol. Additionally, MSY3
localization is independent from cell confluence, since
similar N/C ratios were observed in proliferating cells
at 30 and 80 % of confluency (Fig. 3c). After LY treat-
ment, we observed a robust MSY3 accumulation in the
nucleus both in proliferating and differentiated cells
(Fig. 3a, c and Additional file 1: Figure S5A). A higher
magnification (60×) of the IF shows that in a low per-
centage of the nuclei MSY3 protein is completely de-
pleted (Fig. 3b). When C2C12 cells were treated with
LY in DM, myogenesis was inhibited and mono-
nucleated cells with MSY3 localized in the nuclei were
observed. Although, in some cases, we observed small
myotubes with diffuse MSY3 staining (in nucleus and
cytoplasm) (green arrow in Additional file 1: Figure S5A).
We analyzed the distribution of phosphorylated and de-
phosphorylated MSY3 in the nuclear (N) and (C) cyto-
plasmic compartments in untreated and LY treated
C2C12 myoblasts by Western blot. In concordance with
the IF observations, densitometry measurements showed
that phosphorylated and dephosphorylated forms of
MSY3 protein were distributed equally between the nuclei
and cytoplasm in untreated myoblasts and upon LY treat-
ment the nuclei were enriched for the dephosphorylated
form (Fig. 3d and Additional file 1: Figure S5B). These re-
sults demonstrate that Akt phosphorylation inhibited by
PI3K/Akt pharmacological blockade induces a robust ac-
cumulation of dephosphorylated MSY3 in the nuclei of
myogenic cells. In the nucleus, dephosphorylated MSY3
acts as a transcriptional repressor of differentiation pro-
moting genes, such as myogenin.
Akt phosphorylates MSY3 and reduces its binding to
myogHCE in vitro
To determine if MSY3 is a downstream phospho-
substrate for Akt in vitro, we constructed a GST-MSY3
fusion construct with GST at the N-terminal end and
tested the ability of Akt and GSK3β, another kinase reg-
ulated by the PI3K pathway [47], to phosphorylate
MSY3, in an in vitro kinase assay (Fig. 4a). We observed
that a phospho protein with the same molecular weight
Fig. 3 Dephosphorylated MSY3 accumulates in C2C12 nuclei. a Expression of MSY3 evaluated by IF with anti-MSY3 Ab, ZONAB, in C2C12 myoblasts in
proliferating (30 % confluence) (IF left) and confluent (80 % confluence) growth (IF right) upon LY294002 (LY) treatment. Scale bar = 200 μm. b High
magnification image (60×) of MSY3 expression (top) and Hoechst nuclei staining (bottom) in C2C12 myoblasts untreated (−) and upon LY treatment
(LY). Scale bar = 60 μm. c N/C ratios of MSY3 signal in C2C12 myoblasts untreated (−) and upon LY treatment (+), evaluated as a mean ±DS for 60–80
cells from a total of five independent experiments. Quantification was performed as described in the “Methods” section. *P <0.05 by Student’s t test. d
Densitometry calculations for MSY3 faster (dephosph) and slower (phosph) migration bands in nuclear (N) and cytosolic (C) compartments in untreated
(−) and upon LY treatment (+), analyzed on Western blots performed as that shown in Fig S2B. Figure displays results representative from three
independent RNAi experiments. *P <0.01; **P <0.001 by Student’s t test
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only when the GST-MSY3 protein (but not GST alone)
is incubated with Akt (Fig. 4a lanes 7–8) but not when
it is incubated with GSK3β (Fig. 4a, lanes 11–12). This
evidence confirms that MSY3 is specifically phosphor-
ylated by Akt in myogenic cells. MSY3 represses myo-
genin by binding the highly conserved DNA cis-acting
element located upstream of the myogenin promoter
(myogHCE) (Fig. 4b) [16]. To analyze the functional
impact of MSY3 phosphorylation, we tested if the
binding of MSY3 to the myogHCE regulative element
in vitro is modulated by the Akt phosphorylation of
MSY3. The GST-MSY3 protein binds efficiently to the
WT myogHCE oligo, (MYOwt) but to a lesser extent
to the mutated oligo (MYOmutL) as expected [16] in
a gel shift assay (Fig. 4c, lanes 2–3). We observed that
when MSY3 is phosphorylated in vitro by Akt, its
binding at the myogHCE (MYOwt) element is reduced
more than 50 %, while phosphorylation by GSK3β
showed no effects on binding (Fig. 4c, lanes 4–7). This
result indicates that MSY3 phosphorylation by Akt
shows a moderate but specific effect on the DNA
binding property of the MSY3 recombinant protein.Akt phosphorylates MSY3 in C2C12 cells, decreasing its
binding activity and increasing myogenin expression
In order to further assess if Akt phosphorylation of
MSY3 interferes with its binding of myogHCE in vivo,
we performed chromatin immunoprecipitation (ChIP)
on proliferating (GM) and differentiated C2C12 cells
(DM) treated with the PI3K inhibitor LY, using the anti-
MSY3 Ab ZONAB. ChIP on proliferating C2C12 myo-
blasts treated with LY showed a modest enrichment for
MSY3 at the myogenin promoter compared to untreated
myoblasts. In comparison, C2C12 myotubes treated with
LY showed an increased enrichment when compared to
their untreated counterparts (Fig. 5a). This evidence sug-
gests that Akt inactivation results in increased levels of
dephosphorylated MSY3, which in turn leads to in-
creased MSY3 binding at the myogenin promoter
region.
We also wanted to determine if Akt over-expression
could rescue forced MSY3 repression of myogenin in
C2C12 myoblasts and myotubes. To test this, we trans-
fected MSY3 over-expressing C2C12 pools with a plas-
mid expressing the constitutively active form of Akt
(myristoylated Akt) [61] and measured myogenin
Fig. 4 Akt phosphorylates MSY3 and reduces its binding to myogHCE in vitro. a Phosphorylation of MSY3 by Akt. GST-MSY3 (*) was phosphorylated
by Akt, (lanes 7 and 8) but not by GSK3β (11 12). Auto-phosphorylated Akt protein (°) and GSK3β (§) are present. The Comassie gel is shown
(lanes 1–4). For each sample, there are two experimental replicates. b Schematic of the myogenic locus. This diagram describes the myogenin
promoter (the 130 bp upstream region from the TSS) and the genomic alignments of six vertebrates. The schematic also shows the relative
locations of myogHCE element—the region to which MSY3 binds and other well-known motifs (myogHCE-brown, MEF3box-light blue,
MEF2box-green, TATA box-purple, and E-box-yellow. MyogHCE is MSY3 binding site [16]; MEF3box is Dach2 binding site [13]; MEF2box is
MEF2/HDAC9 binding site [12]. c MSY3 phosphorylation by Akt impairs its binding at the myogenin promoter. Sequences of MyogHCE
(MYOwt) and mutant myogHCE (MYOmutL) oligonucleotides used in EMSA are shown. Mutant MYOmutL disrupts the myogHCE sequence,
which incudes the MSY3 site. Mobility shift assay (EMSA) of GST-MSY3 binding to EMSA assay of GST and GSTMSY3 fusion protein with
myogHCE (MYOwt) and mutant myogHCE (MYOmutL) 32P labeled oligonucleotide in double-strand form without (first three lanes) and with
prior treatment by Akt (lanes 4 and 5) and by GSK3β (lanes 6 and 7)
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Upon Akt expression, we observed modest levels of
myogenin expression at 24 h post-differentiation,
which increased to levels comparable to WT C2C12
cells at later stages of differentiation (72–96 h)(Fig. 5b). These results indicate that forced Akt ex-
pression reduces the amount of dephosphorylated
MSY3 found in the nucleus during forced expres-
sion, thereby reducing its repressive activity on myo-
genin expression in myogenic cells.
Fig. 5 Akt phosphorylates MSY3 in C2C12 cells, decreasing its binding activity and increasing myogenin expression. a Chromatin immunoprecipitation
(ChIP) analysis for control IgG and MSY3 antibodies used individually to enrich fixed chromatin from undifferentiated (GM) or differentiated (DM)
C2C12 cells, treated (+) or not (−) with LY2940002 (LY). qRT-PCR is used to quantify sequences from the myogenin promoter. b Measurements of
endogenous myogenin expression by qRT-PCR in mock transfected C2C12 (−MSY3, −Akt) and MSY3 over-expressing C2C12 multiclones transfected
(+MSY3, +Akt) or not (+MSY3, −Akt) with myristoylated Akt in proliferation medium (GM) or upon different times cultured in differentiation medium
(24–72–96 h DM). GAPDH was used to normalize expression levels
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phosphorylation that alters MSY3 nuclear/cytoplasmic
trafficking and function in myogenic cells
In order to map the putative Akt phosphorylation sites,
we generated FLAG-tagged WT and mutant MSY3 con-
structs, carrying deletions of the domains showed in
Fig. 6a: CSD, alternative splicing domain (SHORT) and
the carboxy (RP-CD) domain, which includes the argin-
ine and proline-rich conserved domain and the C-
terminal proline-rich domain. We introduced these con-
structs by transient transfection in C2C12 myoblasts and
analyzed the migration of their protein products.FLAGMSY3 WT protein migrated as double bands, as
expected. Treatment with AP reduced phosphorylation
levels of the FLAGMSY3 WT protein similar to the en-
dogenous MSY3 protein (Additional file 1: Figure S6).
Among the mutations assayed, only the FLAGΔCSD
showed a strong reduction of the upper band, indicating
that the phosphorylation site responsible for MSY3
phosphorylation in C2C12 cells is located in the CSD
domain (Fig. 6b). It is known that the Akt phosphoryl-
ation site in YB-1 and MSY3 in non-muscle cells was
identified in the CSD. This region is highly conserved
among the cold-shock protein family and is responsible
Fig. 6 Deletion of CSD alters MSY3 nuclear/cytoplasmatic trafficking in myogenic cells. a Graphic illustration of the deleted MSY3 protein
domains tested in the mutagenesis assay and distribution of the Akt phosphorylation consensus sites in the MSY3 protein. b Western blot
with anti-FLAG Ab of protein extract of C2C12 cells transiently transfected with a FLAG-tagged MSY3 protein (FLAGMSY3) and FLAG-tagged
MSY3 protein deleted of the cold shock (FLAGΔCSD), splicing alternative (FLAGΔSHORT), and the carboxy (FLAGΔRP-CD) domains. c FLAG
expression tested by IF with an anti-FLAG Ab in C2C12 myoblasts transiently transfected with FLAGMSY3, FLAGΔCSD, FLAGΔSHORT, and
FLAGΔRP-CD proteins. The white arrow indicates a nuclear FLAG signal of the FLAGΔRP-CD protein. Scale bar = 100 μm. d N/C ratios of FLAG
signal in C2C12 transfected with FLAGMSY3, FLAGΔCSD, FLAGΔSHORT, FLAGΔRP-CD, FLAGSer126Ala, and FLAGSer328Ala proteins, evaluated
as a mean ± DS for 60–80 cells from a total of three independent experiments. Quantification was performed as described in Methods. e Akt
phosphorylation consensus sites in the MSY3 protein
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model, we also identified the CSD as the domain respon-
sible for the nucleus-cytoplasm trafficking. While the
FLAGΔCSD protein localized exclusively in the nucleus
in myoblasts, the FLAGMSY3 and the other mutated
forms localized predominantly in the cytoplasm (Fig. 6c).
An accurate analysis of IF (white arrow in Fig. 6c) and
distribution of phosphorylated and dephosphorylated
MSY3 in the nuclear (N) and (C) cytoplasmic compart-
ments (Fig. 6d), also revealed that the deletion of the C-terminal-domain (RP-CD) induced a partial accumula-
tion of the FLAGΔRP-CD in the nuclei. This modest
nuclear migration of FLAGΔRP-CD protein suggests
that the MSY3 RP-CD domain is at least partially re-
sponsible for MSY3 nucleus-cytoplasmic trafficking. For
instance, it could contain another phosphorylation tar-
get, as indicated by the residual presence of the slower
(phosphorylated) band in the CSD mutant (Fig. 6b).
While searching for Akt phosphorylation consensus se-
quences in the MSY3 protein, we did not find any site
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site RXRXXS/T [63]. However, a PhosphoSitePlus scan of
the MSY3 sequence [64] highlighted several low stringency
putative sites that could potentially be phosphorylated by
Akt (Fig. 6e). Among these we focused on two candidate
amino acids, Serine126 and Serine 328, located in the CSD
and RP-CD domains, respectively. MSY3-Ser126, located in
the CSD, corresponds to Ser102 of the MSY3 human
homolog protein YB-1. Moreover, MSY3Ser126 was shown
to be phosphorylated by Akt in leukemia cell lines [29]. It
has been previously demonstrated that activated Akt phos-
phorylates YB-1 at Ser102, affecting its nuclear transloca-
tion and function in cancer cells [36, 37].
We mutated the Serine 126 and 328 residues to
Alanine in order to remove the side chain substrates and
thus prevent phosphorylation by Akt. Two mutated
MSY-3 constructs (MSY3 Ser126Ala) and (MSY3
Ser328Ala) were constructed and cloned in FLAG
tagged vectors and were transiently expressed in C2C12
myoblasts. Nuclear accumulation of the anti-FLAG sig-
nal was observed only in myoblasts transfected with the
MSY3-S126A but not myoblasts transfected with the
MSY3-S328A construct. This result demonstrates that
Ser126 and not Ser328 is the phosphorylation substrate
responsible for the nuclear trafficking of MSY3 (Fig. 7a).
Also, only Ser126A migrated as a single band, similar to
the CSD mutation, providing further evidence that the
substrate responsible for MSY3 phosphorylation in
C2C12 is Ser126.
We wanted to further determine if Akt over-expression
was able to rescue endogenous myogenin expression in
the presence of the MSY3 mutants (ΔCSD and Ser126A)
in C2C12 myoblasts and myotubes. We transfected mock
N-p3XFLAG-CMV and FLAGΔCSD and FLAGSer126AlaFig. 7 Disruption of Akt substrate Ser126 alters MSY3 nuclear/cytoplasmati
C2C12 myoblasts transiently transfected with FLAG-tagged MSY3 proteins m
Scale bar = 150 μm. Bottom: Western blot with anti-FLAG Ab of protein ext
(FLAGMSY3), FLAGSer126Ala and FLAGSer328Ala. b Measurements of myog
expressing FLAG MSY3, FLAGΔCSD, and FLAGSer126Ala transfected with m
times cultured in differentiation medium (24–72 h DM). GAPDH was used texpressing cell pools with myristoylated Akt and mea-
sured endogenous myogenin expression levels by qRT-
PCR in growth and differentiation conditions (Fig. 7b). In
the myristoylated-Akt transfected cell pools expressing
MSY3 mutant constructs, endogenous myogenin is
strongly reduced relative to those expressing MSY3 WT.
These results demonstrate that the CSD and specifically
Ser126, in the CSD, mediate Akt phosphorylation of
MSY3 and impair its repression of myogenin.
Forced phosphorylation of MSY3 in skeletal muscle tissue
abolishes its binding activity at the myogenin promoter
Our next step was to determine if Akt was able to regu-
late MSY3 phosphorylation and activity in mature
skeletal muscle, as observed in myogenic cells. To an-
swer this question, we forced Akt expression in muscle
fibers by electroporating a TA muscle of an adult mouse
(3 months old, 3MM), with a myristoylated Akt con-
struct (myrsAkt) or a control plasmid (pcDNA3, mock).
Phosphorylated Akt is present at very low levels in adult
muscle, since it is dephosphorylated as muscle matures
(Fig. 8a). When myristoylated, Akt is over-expressed in
muscle and phosphorylates MSY3, as demonstrated by
the shift in the MSY3 protein migration pattern (Fig. 8b).
We also detected a slight increase in myogenin expres-
sion under this condition (Fig. 8b).
Next, we determined if this forced MSY3 phosphoryl-
ation, mediated by constitutive Akt over-expression, im-
paired its binding at the myogenin promoter in mature
muscle. To test this, we performed ChIP with ZONAB on
TA muscle electroporated with myrsAkt. We observed
that, indeed, this forced phosphorylation of MSY3 reduced
its occupancy at the myogenin promoter in adult muscle
(Fig. 8c), leading to myogenin up-regulation. These datac trafficking and function in myogenic cells. a Top: FLAG expression in
utated at Ser126 (FLAGSer126Ala) and at Ser 328 (FLAGSer328Ala).
racts of C2C12 transiently transfected with FLAG-tagged MSY3 protein
enin expression by qRT-PCR in myrsAkt transfected C2C12 multiclones
yristoylated Akt (Akt) in proliferation medium (GM) or upon different
o normalize expression levels
Fig. 8 Forced phosphorylation of MSY3 in skeletal muscle tissue abolishes its binding activity at the myogenin promoter. a Western blot with
anti-phospho and anti-total Akt of protein extracts of limb and TA muscle isolated at different developmental stages, fetal (dpc), and post-
natal days (pn) and mature 1 month (1 M). b Western blot with anti-MSY3 Ab (ZONAB), anti-phospho-Akt, and anti-myogenin of protein
extracts of TA muscle, electroporated with a mock expression plasmid pcDNA3 (mock) and with myristoylated Akt (Akt). Three replicates from
three independent electroporations are shown in lanes 1, 2, 3 and lanes 5, 6, 7. Normalizer is α-tubulin. c Chromatin immunoprecipitation
(ChIP) analysis for control IgG and MSY3 antibodies used individually to enrich fixed chromatin from TA electroporated with a mock expression
plasmid (M) and with myristoylated Akt (Akt). Replicates from three independent electroporations are shown for mock plasmid electroporation
(M1, M2, M3) and for myristoylated Akt (Akt1, Akt2, Akt3). qRT-PCR is used to quantify sequences from the myogenin promoter
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muscle (as observed in myogenic cells in vitro) and as a
consequence both its DNA binding activity and thereby
its function as a repressor, are impaired.
Discussion
Dephosphorylation regulates MSY3 activity in adult
muscle
In skeletal muscle, a fine-tuned regulation of myogenin
expression is required. Muscle functionality depends on
the correct regulation of this muscle regulatory factor,
from the earlier stages of development until maturity, in
normal and in pathological conditions. In Berghella et al.
[16], we proposed a new regulatory pathway, which in-
volves the Y-box protein MSY3/Csda as a negative regu-
lator of myogenin expression in adult muscle. This study
further suggested that muscle functions in postnatal life,
in which myogenin plays a determinant role, are under
the partial control of MSY3. The signaling pathway that
influences MSY3 activity of myogenin regulation from
birth to adulthood is not known [16].
During the progression from fetal to postnatal life and
to late stages of muscle maturation, the phosphorylation
state of the MSY3 long isoform changed, precisely during
the second week after birth. Around this time, we saw a
progressive reduction in myogenin expression. Therefore,
the gradual MSY3 dephosphorylation correlates with aprogressive down-regulation of myogenin. This concur-
rence strongly supports our hypothesis that MSY3 acts as
a repressor when it is dephosphorylated. In the same time
window, we also observed a progressive induction of both
the long and short MSY3 isoforms, although in this study
we did not explore the mechanisms responsible for MSY3
transcriptional regulation. The MSY3 short isoform does
not have the sixth exon but retains the intact CSD do-
main. Unlike the long isoform, the MSY3 short isoform
did not show a high rate of phosphorylation compared to
the long isoform and seems to be regulated only at the
transcriptional level [16]. Hence in this study, we focused
only on the phosphorylation of the long isoform. However,
a more accurate analysis will establish if technical reasons
prevented the detection of the phosphorylated MSY3
short isoform. Phosphorylation has been described as the
main post-transcriptional regulatory mechanism of the Y-
box proteins. Indeed, they are targets for different signal-
ing pathways mediated by protein kinases, which modu-
late or silence Y-box protein function as transcriptional
repressors. In this context, ERK2/MAPK and PI3K/Akt
are the most well-described pathways, the former in in-
creasing the Y-box binding at their targets, and the latter
in inhibiting it [24, 29, 35–38]. In this study, we focused
on the PI3K/Akt pathway, which we demonstrated is re-
sponsible for MSY3 phosphorylation and inhibition of its
activity as a repressor of myogenic gene expression and
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clude the hypothesis that other phosphorylation pathways,
also mediated by phosphatase proteins, may influence
MSY3 function in different stages of skeletal muscle devel-
opment. For instance, it has been recently reported that
serine/threonine protein phosphatase type-1 (PP1) associ-
ates with the cold shock domain of MSY3 [65].
Akt regulates myogenin expression and myogenesis by
MSY3 phosphorylation
In the present work, we discovered a signaling mechan-
ism linking the PI3K/Akt pathway to regulation of myo-
genin expression through phosphorylation of MSY3.
Analysis of the MSY3 protein migration pattern by
Western blot, from differentiating C2C12 myogenic
cells, showed an increase in the phosphorylated MSY3
long isoform. This shift was coincidental with the myo-
genin expression increase and completion of myogenic
differentiation. From our previous studies, we know that
MSY3 binds the myogHCE in the myogenin promoter
and represses myogenin expression in only proliferating
and undifferentiated C2C12 myoblasts and not in myo-
tubes. Moreover, knocking-down MSY3 expression in
myoblasts induced myogenin expression [16]. Our
present study suggests that in order to allow myogenin
expression, MSY3 needs to be inactive and its phosphor-
ylation can be one of the mechanisms by which its func-
tion is inhibited in differentiated muscle. Also, MSY3 is
strongly expressed in the limbs of developing embryos
[66]. At this stage MSY3 is phosphorylated and myo-
genin is highly expressed in somites and in limbs. Based
on these data, we postulate that when MSY3 is
phosphorylated, it is inactive as a repressor and is pre-
dominantly sequestered in the cytoplasm, thus allowing
myogenin expression.
Multiple reports suggest that Y-box proteins are regu-
lated through Akt/PKB-mediated phosphorylation of the
cold shock domain, which is responsible for their regula-
tory activity at the transcription and translation level.
Phosphorylation by Akt, indeed, impairs the inhibitory
activity of the MSY3 homolog, MSY1 (YB-1), and of
MSY3 (YB-2) on oncogenesis progression [29, 36–38].
So, we asked if Akt could also control MSY3 phosphor-
ylation in skeletal muscle. We showed that treatment of
C2C12 cells with the P13K/Akt specific inhibitor,
LY294002 (LY), reduced the phosphorylated MSY3 frac-
tion, both in proliferating and differentiated myogenic
cells. siRNA-mediated depletion of Akt has the same ef-
fect, suggesting a role for Akt in modulating MSY3 ac-
tivity during muscle differentiation. In a cell culture
myogenic system, we demonstrated that silencing Akt
reduced phosphorylated MSY3 levels and concomitantly
myogenin expression and muscle differentiation. We
showed, using a kinase assay, that Akt directly andspecifically phosphorylates recombinant MSY3 in vitro.
While MSY3 might be a GSK3β target since it contains
potential GSK3β sites in the CSD, in our assay it is not
phosphorylated by recombinant GSK3β, in agreement
with previous results [24]. Upon phosphorylation by
Akt, MSY3’s ability to bind its consensus binding site
(myogHCE) on the myogenin promoter in vitro is im-
paired, suggesting a partial role for Akt phosphorylation
in destabilizing the MSY3-myogenin promoter binding
complex formation. Moreover, when Akt activity is
blocked by treatment with LY in differentiating C2C12
cells, MSY3 is able to bind myogHCE, and represses
myogenin expression, but not in untreated C2C12 cells.
Additionally, over-expression of the myristoylated form
of Akt restored myogenin expression in MSY3 over-
expressing myotubes. Altogether, these results demon-
strate that MSY3 phosphorylation by Akt ensures
correct progression of muscle differentiation, by regulat-
ing myogenin expression. When MSY3 is phosphory-
lated, its affinity for myogHCE is reduced and it is
sequestered in the cytoplasm. Cytoplasmic sequestration
then allows the transcription regulatory factors Pbx and
MyoD to access the MSY3 consensus site, thus promot-
ing chromatin opening and gene activation, according to
the model proposed previously [16, 67].
A role of Y-box protein in myogenic differentiation
has also been described previously for YB-1 (MSY1), as
a negative regulator of MyoD expression by binding to
the MyoD core enhancer, cooperatively with a transcrip-
tional repressor, Msx-1 [68]. Moreover, initial evidence
that MyoD might also be directly affected by MSY3 was
previously reported, indicating that both MyoD and
myogenin are modulated by the same repressor complex
[16]. We consider the appealing possibility that Akt
could regulate the nuclear localization of a group of Y-
box proteins, which in turn target myogenic genes, se-
questering them in the cytoplasm thus promoting
muscle differentiation.
Several studies have explained how the PI3K/Akt path-
way affects muscle differentiation through different
mechanisms: by phosphorylation and activation of tran-
scription factors (MyoD) and cofactors (MEF2) or of dif-
ferent components of the muscle transcriptosome
(acetyltransferases, p300, and pCAF), or of proteins that
regulate terminal differentiation and myotube hyper-
trophy [47, 55]. In this study, we propose that the Akt/
MSY3/myogenin signaling cascade acts as a promyo-
genic negative regulatory circuit that proceeds in parallel
with the other positive regulatory pathways controlled
by Akt during muscle differentiation. Hence based on
our findings, PI3K/Akt signaling not only promotes
myogenesis but also actively avoids repression of muscle
differentiation. Previous studies have shown that Akt-
mediated phosphorylation in other contexts can directly
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transcription such as C/EBPα or the Polycomb group
protein Bmi1 to promote cell proliferation or tumor
growth [69, 70]. Moreover, PI3K/Akt pathway inactiva-
tion results in the conversion of chromatin from permis-
sive to repressive, as demonstrated by association of the
Polycomb-associated methyltransferase Ezh2 or in an as-
sociation of MEF2 with myogenesis inhibitors (Ezh2 and
HDAC4) instead of myogenesis activators [55]. Our data
suggests a new mechanism of action by which the PI3K/
Akt pathway prevents myogenic differentiation. Ultim-
ately, Akt acts by direct phosphorylation and inactiva-
tion of a class of negative regulators of muscle
differentiation, the Y-box proteins.
Akt phosphorylation regulates MSY3 nuclei/cytosol
translocation
The underlying mechanism of action mediated by Akt
phosphorylation to exert its function often affects the
substrate sub-cellular trafficking [34, 54]. In cases such
as FOXO, Akt phosphorylation dictates exclusion of the
phosphorylated transcription factors from the nuclei,
leading to inhibition of their transcriptional regulatory
activity [32]. Altering sub-cellular localization is also the
manner in which Akt-mediated phosphorylation modu-
lates Y-box protein functions. Several lines of evidence
show that Y-box proteins act as transcriptional regula-
tors of genes involved in proliferation and differenti-
ation, when they translocate to the nucleus and as
regulators of translation or different functions, when
they are in the cytoplasm [36, 37, 62, 71]. We observed
that inhibiting Akt activity by LY treatment, deleting the
CSD, and mutating the Akt phosphorylation site at
Ser126 in the CSD induced MSY3 protein migration
from the cytoplasm to the C2C12 myogenic cell nucleus.
Although both Ser126 and Ser328 residues are low strin-
gency predicted Akt targets compared to the Akt con-
sensus site (RXRXXS/T), the Ser126 site is conserved
among vertebrates from human to zebrafish. This region
also falls into the highly conserved CSD domain of the
Y-box protein, which is responsible for binding DNA.
This could explain why among the two putative sites,
Ser126 is the substrate for Akt phosphorylation in
MSY3, thus responsible for its nuclear to cytoplasmic
migration. Deletion of the C-domain (ΔRP-CD) induced
a partial migration of flagged MSY3 protein in the nu-
clei, but was confirmed not to be due to the ablation of
the putative Akt phosphorylation site Ser328. It is pos-
sible that the partial migration might have been a result
of the deletion of a region within RP-CD, responsible for
intracellular trafficking or for the conformation and sta-
bility of the protein. Nevertheless, we did not analyze
other Akt putative target sites located in the RP-CD that
could account for the partial nuclear migration observed.Although, we identified the Akt phosphorylation substrate
in MSY3 partially responsible for its nuclear-cytoplasm
translocation, we have yet to determine the mechanism
and the players involved in its subsequent subcellular traf-
ficking. As muscle fibers mature, MSY3 shifts from the
phosphorylated to the dephosphorylated form and trans-
locates from the cytosol to the nuclei, and coincidently,
phosphorylated active Akt is reduced. These results lead
us to believe that the same mechanism of Akt-mediated
phosphorylation of MSY3, determined in myogenic cell
culture, is active during muscle development. We also
postulate that the MSY3 nuclear-cytoplasmic shuttling ob-
served in postnatal muscle is correlated to its function in
repressing myogenin and other possible targets involved
in muscle maturation and growth.
Function of Akt/MSY3 regulatory circuit in adult muscle
The most well-documented role of Akt in skeletal
muscle is to induce hypertrophy in muscle fibers and
maintain muscle mass during development, by control-
ling protein synthesis in muscle fibers, by promoting
proliferation and activation of muscle satellite cells, and
by counteracting atrophy [39, 40]. The negative control
exerted by Akt on MSY3 function as a repressor could
be crucial during perinatal and early postnatal life, when
skeletal muscle grows dramatically and concomitantly
with increased body mass. Contrarily, upon maturity,
when skeletal muscle achieves the right size and it needs
to be maintained, Akt-mediated phosphorylation of
MSY3 is reversed and it is employed in silencing its tar-
get genes. Myogenin is down-regulated in adult and un-
perturbed myofibers. When we forced Akt expression in
adult muscle fibers, we observed phosphorylation of
MSY3 protein with a subsequent over-expression of
myogenin. The phosphorylated MSY3 showed reduced
occupancy at the myogenin promoter thereby allowing
myogenin reactivation. Forced Akt expression was con-
fined to muscle fibers and not observed in satellite cells,
and it was accompanied by an increase of muscle fiber
size (data not shown) as already described [44, 72]. This
evidence suggests that the Akt/MSY3 regulatory axis
may be involved in a possible mechanism to control
muscle size within myofibers. It is possible that upon
phosphorylation, MSY3 binding of other genomic targets
required for skeletal muscle growth and maturation is
also impaired. This is plausible considering that myo-
genin deletion in early postnatal life does not affect skel-
etal muscle growth [4], and Akt/MSY3 might control
mechanisms independent of myogenin in this context.
Further genome-wide studies on MSY3 occupancy will
address this point.
In our previous work, we proposed a role of MSY3/
Csda in neuromuscular junction (NMJ) development oc-
curring during skeletal muscle innervation due to its
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AChRs along muscle fibers [16]. Other mechanisms have
been described that respond to nerve signals in order to
down-regulate myogenin and involve transcriptional re-
pressors [12, 13, 31]. As Akt regulates MSY3 function, it is
likely that the PI3K/Akt pathway participates in nerve-
mediated signaling, occurring during motor innervation.
Nevertheless, a link between nerve activity and Akt activa-
tion has not been described yet. It has been well described
how Akt activation can be promoted by intracellular cal-
cium increase [73, 74], although the signaling cascade that
precedes the dephosphorylation of MSY3 in mature
muscle and whether other MRFs are involved in this
timed process is currently unknown. Additionally, it is
possible that other post-translational modifications of the
MSY3 protein could act in order to connect electrical ac-
tivity of the nerve to myogenin via MSY3.
In adult life, myogenin is reinduced following injuries
in satellite cells or upon resection of the sciatic nerve
(denervation) in muscle fibers [57, 75]. The PI3K signal-
ing pathway plays an active role in response to regener-
ation of damaged muscle. In satellite cells, Akt promotes
muscle gene expression and terminal differentiation
through different cooperating targets [55, 76, 77]. It is
plausible that the Akt/MSY3/myogenin regulatory cir-
cuit drives myogenesis in satellite cells upon injury and
thus contributes to muscle fiber growth through mecha-
nisms mediated by satellite cells.
Some studies showed that when denervation is in-
duced in muscle, active pAkt and total Akt are signifi-
cantly and unexpectedly up-regulated [78]. The reason
for Akt activation still remains unknown, although it can
be explained as a compensatory effect to counteract
denervation-induced muscle atrophy. Indeed, constitu-
tively active Akt can inhibit neurogenic atrophy [43].
Additionally, we have previously shown that MSY3 pro-
tein levels start to decrease upon denervation followed
by an increase in myogenin and Myod expression levels.
Conversely, it was shown that forced expression of
MSY3 (electroporated) in denervated muscle led to a
knockdown of myogenin, Myod, and α AChR expres-
sions with no effect on MCK and ℇ AChR expressions
[16]. When reactivated, Akt could phosphorylate MSY3
and hence promote myogenin or other MSY3 targets
derepression upon nerve section. In this study, we did
not explore the downstream effects of Akt over-
expression in muscle fibers, although using transgenic
models over-expressing Akt will help elucidate the role
of the Akt/MSY3 regulatory circuit in the conditions
when myogenin is re-expressed.
Conclusions
Altogether, these results propose a new mechanism of ac-
tion for the PI3K/Akt pathway in controlling myogenicdifferentiation and possibly adult muscle function by dir-
ect phosphorylation of MSY3. In a myogenic cell culture
model, we demonstrated that Akt modulates the activity
of MSY3, a repressor of myogenic differentiation. Akt
phosphorylation of MSY3 inhibits its repression of myo-
genin, thereby turning on myogenin expression upon dif-
ferentiation. In adult myofibers, the Akt/MSY3 regulatory
circuit is involved in down-regulating and maintaining
low myogenin expression levels, in turn controlling adult
skeletal muscle growth and metabolism. These results
support the hypothesis that the key components of the
PI3K/Akt signaling pathway that control myogenin
expression in muscle fibers are potential therapeutic tar-
gets for therapies to control muscle regeneration and
degeneration.Additional file
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